Kezar Life Sciences, Inc. (KZR)

NASDAQ: KZR · IEX Real-Time Price · USD
8.80
+0.19 (2.21%)
At close: Oct 3, 2022 4:00 PM
8.98
+0.18 (2.05%)
After-hours: Oct 3, 2022 7:46 PM EDT
2.21%
Market Cap 601.65M
Revenue (ttm) n/a
Net Income (ttm) -60.89M
Shares Out 68.37M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 422,276
Open 8.51
Previous Close 8.61
Day's Range 8.47 - 8.91
52-Week Range 4.31 - 18.55
Beta 0.15
Analysts Buy
Price Target 19.13 (+117.4%)
Earnings Date Nov 7, 2022

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products includ... [Read more...]

Industry Biotechnology
IPO Date Jun 21, 2018
CEO John Fowler
Employees 56
Stock Exchange NASDAQ
Ticker Symbol KZR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for KZR stock is "Buy." The 12-month stock price forecast is 19.13, which is an increase of 117.39% from the latest price.

Price Target
$19.13
(117.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 hours ago - Business Wire

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

4 days ago - Business Wire

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...

1 month ago - Business Wire

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 month ago - Business Wire

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 month ago - Business Wire

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...

2 months ago - Business Wire

Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?

The mean of analysts' price targets for Kezar Life Sciences, Inc. (KZR) points to an 81.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

2 months ago - Zacks Investment Research

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

2 months ago - Business Wire

Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

2 months ago - Business Wire

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...

Other symbols: BBCDAWNLYELMRTXRPTX
3 months ago - Zacks Investment Research

Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiveness of this highly sought-after metric is question...

3 months ago - Zacks Investment Research

Wells Fargo Beefs Up Kezar Life Price Target - Read Why

Wells Fargo reiterated its Overweight rating and raised its price target to $17 from $13 for Kezar Life Sciences Inc (NASDAQ: KZR) on zetomipzomib's (zeto) positive Ph2 MISSION data in lupus nephritis (...

3 months ago - Benzinga

Why Kezar Life Sciences Stock Is Crushing It Today

A positive phase 2 data readout is lighting a fire underneath the biotech's shares today.

3 months ago - The Motley Fool

Kezar (KZR) Doubles on Promising Kidney Disorder Study Data

Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.

3 months ago - Zacks Investment Research

Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results

Shares of Kezar Life Sciences are up an astounding 74% today after the biotechnology company reported positive results from its clinical trial regarding a treatment for the autoimmune disease Lupus. The...

3 months ago - InvestorPlace

After-Hours Action: Why Kezar Life Sciences Stock Is Soaring

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. Zeto...

3 months ago - Benzinga

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

3 months ago - Business Wire

Billionaire Israel Englander Is Betting Big on These 5 Stocks

Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. The post Billionaire Israel Englander Is Betting Big on These 5 Stocks appeared fir...

Other symbols: EGYFBRTTCMD
3 months ago - InvestorPlace

Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a Turnaround

Kezar Life Sciences, Inc. (KZR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst...

3 months ago - Zacks Investment Research

3 Biotech Stocks to Buy Before They Boom

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on Inves...

Other symbols: KYMRPTGX
4 months ago - InvestorPlace

After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)

The heavy selling pressure might have exhausted for Kezar Life Sciences, Inc. (KZR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str...

4 months ago - Zacks Investment Research

Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Kezar Life Sciences, Inc. (KZR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions c...

4 months ago - Zacks Investment Research

Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

4 months ago - Business Wire

Should You Buy Kezar (KZR) Ahead of Earnings?

Kezar (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges

Wells Fargo is reiterating its Overweight rating after Kezar Life Sciences Inc's (NASDAQ: KZR) zeto (KZR-616) Phase 2 trial in dermatomyositis/polymyositis failed to top placebo on the trial's primary e...

4 months ago - Benzinga